Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 28, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons in the company's Ordinary Shares, specifically regarding the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes and Transactions
The following transactions involving the GlaxoSmithKline Employee Trust were reported:
- February 23, 2006: The Trustees sold 127,342 Ordinary Shares on behalf of participants in the GlaxoSmithKline Performance Share Plan at a price of GBP 14.65 per share.
- February 23, 2006: The Trustees transferred 291,943 Ordinary Shares to participants in the GlaxoSmithKline Performance Share Plan.
- February 24, 2006: The Trustees transferred 14,584 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Three directors (Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific share transactions noted above.
Investor Verification Checklist
- Verify the impact of the reported share sales and transfers on the total outstanding share count.
- Confirm the current status of the GlaxoSmithKline Performance Share Plan and the SmithKline Beecham Employee Share Option Plan 1991.
- Review the specific interests of Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop in the GSK Trust.